155
Views
7
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Recipient and donor JAK2 46/1 haplotypes are associated with acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation

, , , , , , , , , , , , & show all
Pages 391-398 | Received 22 Feb 2016, Accepted 31 May 2016, Published online: 07 Jul 2016
 

Abstract

Several genetic polymorphisms have been implicated to affect the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT). The role of cytokines in acute graft-versus-host disease (aGvHD) is well established and many of the involved cytokines signal through the Janus kinase (JAK) pathways. In this study, we assessed the association of recipient and donor JAK2 46/1 haplotypes and allo-HSCT outcome in a cohort of 124 acute myeloid leukemia patients. Both, recipient and donor 46/1 haplotypes significantly affected aGvHD grades II–IV development (p = 0.006 and p = 0.031, respectively), furthermore the influence of the haplotypes seemed to be additive. In multivariate analyses the recipient haplotype remained independently related (p = 0.012) to aGvHD, while the donor not (p = 0.08). We observed significantly less relapses among haplotype carriers (p = 0.004), but overall survival did not differ (p = 0.732). Our findings suggest that recipient and donor JAK2 46/1 haplotypes might be involved in the regulation of aGvHD.

Acknowledgements

The authors wish to thank Csehne Banhidi Klara, Haluska Brigitta, Mezibroczky Martina, and Petro Peterne for their technical assistance and Tatai Gabor for data management.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at http://www.w3.org/10.1080/10428194.2016.1198956.

Funding information

This work was supported by grants from the Hungarian Scientific Research Fund [grant number OTKA K104903].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.